Coverage of Amarin off-label promotion agreement should have acknowledged deadly history of such marketing
Xarelto controversy highlights need for more transparency at NEJM
Investigation of Alzheimer’s Association in-fighting didn’t address the role of corporate sponsorships
“Low T” tease: rosy anecdotes and the reality of testosterone treatment effects
Groups push pharma agenda under the guise of patient advocacy
Faulty medical devices stay on the market even after manufacturers know there are problems
University of Maryland launches institutional review of chocolate milk study first flagged by HealthNewsReview.org
Grail’s search for a universal cancer screen: noble quest or fool’s errand?
Hypewatch: Journalists need to pour some cold water into that “Grail”
Is more testing really the way to save American healthcare?